Patents by Inventor Xiaoniu MIAO
Xiaoniu MIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230357422Abstract: Related is a single-domain antibody targeting 4-1BB, a fusion protein thereof, a pharmaceutical composition and a use thereof. Specifically, the related single-domain antibody comprises one heavy chain variable region, and the amino acid sequences of CDR1-CDR3 contained in the heavy chain variable region are as shown in any item in table B, respectively. The single-domain antibody can bind to human 4-1BB and at the same time cross-bind to cynomolgus 4-1BB; in addition, with the help of external cross-linking, T cells are activated, which have excellent anti-tumor activity and safety.Type: ApplicationFiled: September 17, 2021Publication date: November 9, 2023Inventors: Tianhang ZHAI, Xiaoniu MIAO, Yifeng XU, Chao WANG, Andy TSUN
-
Publication number: 20230348627Abstract: The present invention relates to an anti-4-1BB-anti-PD-L1 bispecific antibody, and a pharmaceutical composition and the use thereof. Specifically, the present invention relates to a bispecific antibody, which comprises a first protein functional region targeting 4-1BB and a second protein functional region targeting PD-L1 or PD-1, wherein the first protein functional region is a single-domain antibody against 4-1BB; and the second protein functional region is an anti-PD-L1 antibody, anti-PD-1 antibody, anti-CTLA-4 antibody or anti-HER-2 antibody, or an antigen-binding fragment thereof. The bispecific antibody has the function of blocking the binding of PD-L1 to a receptor PD-1, and binds to 4-1BB on an immune cell, such that the immune cell activity in a tumor microenvironment is activated and the effect of inhibiting tumor occurrence and development is improved more effectively.Type: ApplicationFiled: September 17, 2021Publication date: November 2, 2023Inventors: Tianhang ZHAI, Xiaoniu MIAO, Yingda XU, Tao WANG, Andy TSUN, Weifeng HUANG
-
Publication number: 20230340158Abstract: The present invention relates to the field of biomedicine and specifically relates to an anti-VEGF-anti-PD-L1 bispecific antibody, a pharmaceutical composition of same, and uses thereof. Specifically, the present invention relates to the bispecific antibody, which comprises: a VEGF-targeted first protein functional area and a PD-L1-targeted second protein functional area, wherein: the first protein functional area is an anti-VEGF antibody or an antigen-binding fragment thereof, or, the first protein functional area comprises a VEGF receptor or a fragment having a VEGF receptor function, and the second protein functional area is an anti-PD-L1 monoclonal antibody. The bispecific antibody of the present invention is capable of activating the immune system and blocking tumor angiogenesis at the same time, and provides great antitumor prospects.Type: ApplicationFiled: August 30, 2021Publication date: October 26, 2023Inventors: Xiaoniu Miao, Cheng CHEN, Zhijun YUAN, Weifeng HUANG, Andy TSUN, Joanne TSOYUE
-
Publication number: 20230312739Abstract: The present invention relates to the field of disease therapy and immunology. Specifically, disclosed are an anti-CD73 antibody or an antigen-binding fragment thereof, a nucleic acid molecule encoding same, an immunoconjugate comprising same, a bispecific molecule and a pharmaceutical composition, as well as use thereof in enhancing immune response and/or treating tumors.Type: ApplicationFiled: August 28, 2020Publication date: October 5, 2023Inventors: Liang DU, Hongyan ZHANG, Lina JIN, Yali CHEN, Jijun YUAN, Zhenqing ZHANG, Xiaoniu MIAO, Weifeng HUANG, Yunli JIA
-
Patent number: 11746148Abstract: The present invention provides an artificially designed antibody molecule comprising four polypeptide chains, where each of the first polypeptide chain and the third polypeptide chain comprises an immunoglobulin light chain, and each of the second polypeptide chain and the fourth polypeptide chain comprises, from the N-terminus to the C-terminus, an immunoglobulin heavy chain variable region, an immunoglobulin CH1 domain, a VHH, an immunoglobulin CH2 domain, an immunoglobulin CH3 domain, and optionally an immunoglobulin CH4 domain. The present invention also provides a polynucleotide encoding the antibody molecule, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, an immunoconjugate and a pharmaceutical composition comprising the antibody molecule, and use of the antibody molecule in the immunotherapy, prevention and/or diagnosis of diseases.Type: GrantFiled: March 26, 2019Date of Patent: September 5, 2023Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Junjian Liu, Xiaoniu Miao, Zhihui Kuang
-
Patent number: 11732044Abstract: The invention relates to a novel antibody and an antibody fragment thereof that specifically bind to ALG-3 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment. In particular, the invention relates to combination therapy of the antibodies and the antibody fragments described herein with other therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.Type: GrantFiled: December 27, 2018Date of Patent: August 22, 2023Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Xiaoniu Miao, Huajing Hu, Andy Tsun, Junjian Liu, Xiaolin Liu
-
Patent number: 11708417Abstract: An antibody that specifically binds to a glucocorticoid-induced tumor necrosis factor receptor (GITR), an antibody fragment and a polymer thereof, and a conjugate and a fusion comprising the antibody or the antibody fragment are provided in the present invention. A nucleic acid encoding the antibody, the antibody fragment, the polymer, the conjugate and the fusion, a vector, and a host cell expressing the nucleic acid are also provided in the present invention. In addition, a composition comprising the antibody and the antibody fragment thereof, the polymer, the conjugate or the fusion, and use thereof in therapy and diagnosis are also provided in the present invention.Type: GrantFiled: March 26, 2019Date of Patent: July 25, 2023Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTDInventors: Xiaoniu Miao, Zhihui Kuang, Weifeng Huang, Junjian Liu
-
Publication number: 20230203167Abstract: A PD-L1 nano-antibody and a PD-L2 nano-antibody, and a bispecific antibody having both the PD-L1 nano-antibody and the PD-L2 nano-antibody are disclosed. The bispecific antibody can block PD-1/PD-L1 and PD-1/PD-L2 pathways at the same time. The bispecific antibody can reactivate T cells, enhance immune responses, and more effectively improve the inhibitory effect on tumor occurrence and development.Type: ApplicationFiled: March 30, 2021Publication date: June 29, 2023Inventors: Xiaoniu MIAO, Fan WU, Cheng CHEN
-
Publication number: 20230167200Abstract: Provided in the present invention is a method for constructing a multispecific antibody. The method comprises the steps of: (i) constructing a first polynucleotide and a second polynucleotide, respectively, wherein the first polynucleotide and the second polynucleotide respectively encode a first polypeptide containing a CL region and a second polypeptide containing a CH1 region, and a disulfide bond may be formed between the CL region of the first polypeptide and the CH1 region of the second polypeptide, such that the antibody has a heterodimeric form; and (ii) expressing the first polynucleotide and the second polynucleotide to obtain the first polypeptide and the second polypeptide, and dimerize the first polypeptide and the second polypeptide to form a multispecific antibody with a heterodimeric form.Type: ApplicationFiled: March 30, 2021Publication date: June 1, 2023Inventors: Xiaolin LIU, Andy TSUN, Tsoyue Joanne SUN, Xiaoniu MIAO, Tao WANG, Shuang DAI
-
Publication number: 20230002503Abstract: Provided are an anti-CAIX single-domain antibody and a VHH chain thereof, as well as related coding sequence, expression vector and host cell; also provided are a production method for said CAIX single-domain antibody and an application thereof.Type: ApplicationFiled: August 25, 2020Publication date: January 5, 2023Inventors: Xiaoniu MIAO, Yifeng XU, Gang YI, Zhiyuan LI, Andy TSUN, Xiaolin LIU
-
Patent number: 11512131Abstract: The invention relates to a novel antibody and an antibody fragment that specifically bind to PD-L1 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and a related use. Furthermore, the invention relates to a therapeutic and diagnostic use of these antibodies and antibody fragments. Particularly, the invention relates to a combined treatment of these antibodies and antibody fragments with other therapies.Type: GrantFiled: December 27, 2018Date of Patent: November 29, 2022Assignee: Innovent Biologies (Suzhou) Co., Ltd.Inventors: Xiaoniu Miao, Huajing Hu, Junjian Liu, Bingliang Chen, Li Li
-
Patent number: 11485795Abstract: The present invention provides an antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), an antigen-binding fragment of the antibody, and a composition comprising the antibody or the fragment. Also provided are a nucleic acid that encodes the antibody or the fragment, a host cell containing the nucleic acid, and applications of the antibody and fragment in treatment and diagnosis.Type: GrantFiled: December 22, 2017Date of Patent: November 1, 2022Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTDInventors: Andy Tsun, Eric Krauland, Jonathan P Belk, Xiaoniu Miao, Min Zhang, Nadthakarn Boland, Xiaolin Liu, Dechao Yu
-
Publication number: 20220267458Abstract: An antibody that specifically binds to a glucocorticoid-induced tumor necrosis factor receptor (GITR), an antibody fragment and a polymer thereof, and a conjugate and a fusion comprising the antibody or the antibody fragment are provided in the present invention. A nucleic acid encoding the antibody, the antibody fragment, the polymer, the conjugate and the fusion, a vector, and a host cell expressing the nucleic acid are also provided in the present invention. In addition, a composition comprising the antibody and the antibody fragment thereof, the polymer, the conjugate or the fusion, and use thereof in therapy and diagnosis are also provided in the present invention.Type: ApplicationFiled: March 26, 2019Publication date: August 25, 2022Inventors: Xiaoniu MIAO, Zhihui KUANG, Weifeng HUANG, Junjian LIU
-
Publication number: 20220227870Abstract: The present invention provides a novel artificial triple-chain antibody comprising three polypeptide chains, wherein a first polypeptide chain comprises a first heavy-chain variable domain, a second polypeptide chain comprises a first light-chain variable domain that is paired with the first heavy-chain variable domain to form a first antigen-binding site; and a third polypeptide chain comprises a second single-domain antigen-binding site and a third single-domain antigen-binding site. The present invention also provides a polynucleotide encoding the triple-chain antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, an immunoconjugate comprising the triple-chain antibody and a pharmaceutical composition comprising the triple-chain antibody or the immunoconjugate thereof, and use of the triple-chain antibody in immunotherapy, prevention and/or diagnosis of diseases.Type: ApplicationFiled: December 26, 2018Publication date: July 21, 2022Applicant: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Xiaoniu MIAO, Zhihui KUANG, Huajing HU, Haiqing NI, Junjian LIU
-
Patent number: 11274153Abstract: Disclosed is a nanobody against the human programmed death factor PD-LI. The antibody has the function of blocking the binding of PD-LI to the receptor PD-I. Disclosed are the nanobody and the gene sequence encoding the nanobody, the corresponding expression vector and the host cell capable of expressing the nanobody, and the method for producing the nanobody. At the same time, also disclosed is the sequence of the humanized PD-LI nanobody. The humanized nanobody still has the function of blocking the binding of PD-LI to PD-1, and has a relatively high affinity and a relatively good specificity.Type: GrantFiled: August 3, 2017Date of Patent: March 15, 2022Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Xiaoning Shen, Xiaoniu Miao, Xiaolin Liu
-
Publication number: 20220041702Abstract: The present invention provides a novel, artificially designed antibody molecule comprising: (i) single-domain antigen-binding sites; (ii) antigen-binding Fab fragments; wherein the single-domain antigen-binding site is located at the N-terminus of a light chain variable domain (VL) of the antigen-binding Fab fragment or the C-terminus of a light chain constant region (CL) of the antigen-binding Fab fragment or the single-domain antigen-binding site is located at the N-terminus of a heavy chain variable domain (VH) or the C-terminus of an immunoglobulin CH1 domain of the antigen-binding Fab fragment, the single-domain antigen-binding site and the antigen-binding Fab fragment bind to the same antigen or different antigens, and the single-domain antigen-binding site and the antigen-binding Fab fragment have or do not have a linker peptide therebetween; and (iii) immunoglobulin Fc domains located at the C-terminus of the single-domain antigen-binding site or the antigen-binding Fab fragment.Type: ApplicationFiled: March 26, 2019Publication date: February 10, 2022Inventors: Junjian LIU, Xiaoniu MIAO, Zhihui KUANG
-
Publication number: 20210371529Abstract: The invention relates to a novel antibody and an antibody fragment thereof that specifically bind to ALG-3 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment. In particular, the invention relates to combination therapy of the antibodies and the antibody fragments described herein with other therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.Type: ApplicationFiled: December 27, 2018Publication date: December 2, 2021Inventors: Xiaoniu MIAO, Huajing HU, Andy TSUN, Junjian LIU, Xiaolin LIU
-
Publication number: 20200332009Abstract: The invention relates to a novel antibody and an antibody fragment that specifically bind to PD-L1 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and a related use. Furthermore, the invention relates to a therapeutic and diagnostic use of these antibodies and antibody fragments. Particularly, the invention relates to a combined treatment of these antibodies and antibody fragments with other therapies.Type: ApplicationFiled: December 27, 2018Publication date: October 22, 2020Inventors: Xiaoniu Miao, Huajing Hu, Junjian Liu, Bingliang Chen, Li Li
-
Publication number: 20200087416Abstract: The present invention provides an antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), an antigen-binding fragment of the antibody, and a composition comprising the antibody or the fragment. Also provided are a nucleic acid that encodes the antibody or the fragment, a host cell containing the nucleic acid, and applications of the antibody and fragment in treatment and diagnosis.Type: ApplicationFiled: December 22, 2017Publication date: March 19, 2020Inventors: Andy TSUN, Eric KRAULAND, Jonathan P BELK, Xiaoniu MIAO, Min ZHANG, Nadthakarn BOLAND, Xiaolin LIU, Dechao YU
-
Publication number: 20190023793Abstract: Disclosed is a nanobody against the human programmed death factor PD-LI. The antibody has the function of blocking the binding of PD-LI to the receptor PD-I. Disclosed are the nanobody and the gene sequence encoding the nanobody, the corresponding expression vector and the host cell capable of expressing the nanobody, and the method for producing the nanobody. At the same time, also disclosed is the sequence of the humanized PD-LI nanobody. The humanized nanobody still has the function of blocking the binding of PD-LI to PD-1, and has a relatively high affinity and a relatively good specificity.Type: ApplicationFiled: August 3, 2017Publication date: January 24, 2019Applicant: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Xiaoning SHEN, Xiaoniu MIAO, Xiaolin LIU